How the FDA is Becoming a Drug Company-Consumer Safety and Access to Natural Health Options Threatened

[Guest guest]

http://www.newstarget.com/021900.html

Originally published June 14 2007

How the FDA is Becoming a Drug Company: Consumer Safety and Access to

Natural Health Options Threatened

by Byron J. Richards, CCN

 

Under the false pretense of improved food and drug safety the FDA is

re-inventing itself as a kingpin drug company. This charade has so far

hoodwinked virtually all members of Congress. The Senate has already

approved this FDA transformation. The House will bring similar legislation

out of committee next week, with a vote in the full House likely in July.

The measure will then go to a conference committee to work out the

differences. The final chapter in this transformation occurs when the

Reagan-Udall Foundation for the FDA becomes law, which is scheduled to

happen some time before September 30, 2007.

 

Even well-intended FDA employees are actively seeking new employment in more

meaningful work. Such is the case with Rosemary Johann-Liang, former FDA

deputy director of the Division of Drug Risk Evaluation. Last year she was

reprimanded for trying to put a black box warning on Avandia, a move the FDA

itself made last week in a damage-control effort to cover its complicity

with GlaxoSmithKline. After 6 1/2 years Johann-Liang is leaving the FDA. As

USA Today reports:

 

She begins working Monday as chief medical officer in the vaccine injury

compensation program at the federal Health Resources and Services

Administration. Still, she says, she might have tried to figure out how to

stay at the FDA " if the agency had a vision of promoting and protecting

public health. "

 

The 10,000 or so laid off Pfizer employees should cheer up, gainful

employment for a legion of drug reps will soon be available through spin-off

companies of the FDA's Regan-Udall Foundation. Yes indeed, times are a

changing.

 

 

How Did this Happen?

The Bush administration figured out that the fastest way to get the FDA out

of the way of Big Pharma's profits was to appoint FDA critics to key

positions, thereby changing the FDA from within. This began in August of

2001 when Bush appointed Daniel Troy as chief counsel of the FDA, a man best

known for defending tobacco companies. Mr. Troy invited Big Pharma to submit

cases to him so that the FDA could help Big Pharma defeat citizens who were

complaining that drugs and medical devices injured them. This has resulted

in legal case precedent that ties up damage claim cases indefinitely and

creates " trade secret laws " wherein the FDA claims it is legally obligated

to withhold drug risks from the public to protect Big Pharma's proprietary

knowledge.

 

Another active critic of the FDA, Scott Gottlieb, M.D., a Wall Street

biotech sales rep and member of the American Enterprise Institute was

invited into the FDA to rewrite its medical policy. Shortly after that Bush

appointed him to the number two position at the FDA, even though he was a

young and inexperienced physician with no expertise in drug safety -- just a

major agenda to bring unproven drugs to the market with far less safety or

effectiveness testing for the benefits of Wall Street.

 

These appointments were just warm-ups for Bush. His appointment that floored

the drug-safety world and sent well-intentioned FDA employees running for

cover was the appointment of Andrew von Eschenbach to head the FDA, an

appointment that the Senate made permanent in last year's Lame Duck session.

The FDA is now headed by a representative of the pharmaceutical and biotech

industries. It is informative to understand the chain of events enabling von

Eschenbach to attempt his transformation of the FDA into a drug company.

 

 

C-Change

Andrew von Eschenbach is a founding member of C-Change, short for Cancer

Change (originally called The National Dialogue on Cancer) -- a group that

was created and funded in 1998 by the American Cancer Society. This group

has become a conglomeration of the most powerful players in the cancer

treatment industry, as can readily be judged by looking at their member

list. Their unstated goal is taking the national cancer agenda away from the

public sector and placing it into private for-profit hands. The group is

headed by former President Bush and his wife, Barbara. Until recently von

Eschenbach was the vice chairman of the board. Since becoming permanent head

of the FDA he relinquished his board position and is now only a member.

 

Von Eschenbach is an oncologist by trade, a cancer survivor himself, and had

a long career running the MD Anderson Cancer Center in Texas. He parlayed

his close relationship with the Bushes and cancer-industry players into an

appointment to head the National Cancer Institute (January 2002). And thus

began the final stages in the transfer of power from public health interests

to Big Pharma and Big Biotech. The initial and extensive C-Change conflicts

of interest are fully explained in a revealing article on the Cancer

Prevention Coalition website, including the assistance of tobacco companies

and their PR firms in setting up this arrangement.

 

On February 22, 2002, Diane Feinstein (D-CA), the only Senator that is a

member of C-Change, introduced The National Cancer Act of 2002 (S.1976).

While this legislation never became law, it was quite telling as regards the

C-Change plan -- to shift the national cancer agenda and funding away from

the public interest and into the hands of the American Cancer Society,

C-Change, and related pharmaceutical companies.

 

Astonishingly, then director of Health and Human Services Tommy Thompson

approved a waiver allowing von Eschenbach to remain vice chairman of

C-Change while heading NCI, a dramatic conflict of interest. Tommy Thompson,

like von Eschenbach, is a founding member of C-Change. During the von

Eschenbach rein at NCI hundreds of millions of dollars in research grants

were channeled to his C-Change friends and away from basic cancer research

and public health measures relating to easily preventable cancers.

 

As head of NCI, von Eschenbach reorganized its administration bringing in a

new layer of management spearheaded by the chairperson of the C-Change

cancer research team and former biotech CEO, Anna Barker, Ph.D. Part of this

new team included C-Change member Mark Clanton, M.D., as deputy director for

cancer care and delivery. This C-Change management team met behind closed

doors, setting NCI priorities independent of NCI's traditional scientific

advisors.

 

Von Eschenbach then funneled NCI money into Big Biotech projects relating to

genomic-based cancer research, nanotechnology, proteomics, and the

establishment of biomarkers relating to disease and cancer identification.

While such innovative projects are on the one hand admirable, they are quite

detached from the real-world issues that cause cancer in many Americans and

are in many ways a diversion from what should be done now to realistically

help many people not get cancer. Furthermore, there is no near-term tangible

result. The problem for all of this type of research is how to get potential

products to the market when the cost for drug development is so high and the

FDA has no guidelines as to how these drugs even work or can be monitored

for safety.

 

 

The Critical Path Initiative

The FDA " solution " to this problem, announced in March of 2004, was to set

up a collaboration with industry to design the next generation of drugs.

This plan is called the Critical Path Initiative and it refers to

streamlining the path for approval to get new drugs on the market faster

with less expense and less testing for safety or effectiveness. I would like

to point out that the entire Critical Path Initiative, admirable as it may

seem to some, is going to produce an increase in public health disasters

like Vioxx. This is because the FDA (or more specifically von Eschenbach and

friends) think the pharmaceutical industry's problems are all based on a

failure to get approval of new drugs fast enough.

 

In reality, the pharmaceutical industry's real problem is a failure to get

results in the marketplace. When a new drug is approved very little is

actually known about how it will perform in the real world. This problem is

complicated by direct to consumer promotion that typically misrepresents the

drug, massive off label promotion and use of the drug, and no system that

monitors what is really happening with the drug as it is used. By rushing

more drugs onto the market faster, the failure to get results issue will be

magnified -- and the safeguards proposed in S.1082 are inadequate. Any

savings in the cost of bringing a drug to market will be offset by the costs

of lawsuits related to damages. The FDA is trying to " solve " that problem by

preventing citizens from suing drug companies when an FDA-approved drug

injures or kills. Von Eschenbach and the FDA have pushed forward with this

very misguided marketing strategy.

 

In June of 2004 von Eschenbach's NCI awarded SRI International a long term

grant to evaluate the safety and pharmacology of these new biological drug

cancer treatments. More related grants have followed. SRI specializes in

cancer biology and toxicology research, as well as helping to patent,

license, and spin off inventions into commercial applications. SRI also does

extensive work for the Department of Defense and Homeland Security. Some of

SRI's largest clients besides government are the Rockefeller Foundation, the

Ford Foundation, and the Bill and Melinda Gates Foundation.

 

In March of 2005 the FDA announced its first Critical Path collaboration

known as the C-Path Institute in Tucson, Arizona. This is a collaboration

between the University of Arizona, the FDA, and SRI International. One of

its first projects is the establishment of cardiovascular biomarkers,

working in conjunction with the University of Utah. Following this

announcement the governors of the States of Arizona and Utah joined

C-Change.

 

Conflict of interest reached a new level in October of 2005 when President

Bush appointed von Eschenbach as temporary head of the FDA, a position he

took while maintaining his roles as head of NCI and as vice chairman of the

board of C-Change.

 

 

The Reagan-Udall Foundation for the FDA

Once von Eschenbach took over at the FDA, and eventually gave up his role at

NCI, his main priority became promoting the Critical Path Initiative (not

food or drug safety). He worked diligently with Senators Mike Enzi (R-WY)

and Edward Kennedy (D-MA) to create a vehicle within the FDA to develop the

next generation of biotech drugs. In last year's version of this legislation

(which never came out of committee), this project was called The

Reagan-Udall Institute for Applied Biomedical Research. This legislation

would have set up the Institute within the FDA.

 

This year, Kennedy and Enzi tacked this piece of legislation onto required

FDA funding, lumping numerous FDA issues into one huge bill (S.1082) and

telling everyone it is a safety bill. Within this new legislation is the

creation of the Reagan-Udall Foundation for the FDA, set up as an

independent non-profit Foundation that will be under the control of the FDA.

The Senate fought bitterly over various drug-safety issues unrelated to the

Reagan-Udall Foundation, as if these issues acted as a smoke screen to slip

past members of the Senate the creation of the Reagan-Udall Foundation for

the FDA, the von Eschenbach dream come true.

 

Not a single Senator raised one concern about the significant safety issues

inherent in the Critical Path Initiative/Reagan-Udall Foundation or

conflicts of interest when Big Pharma and the FDA work side by side to

develop, patent, and license drugs. The entire history of von Eschenbach's

relationship with Big Pharma, Big Biotech, and C-Change has been

conveniently ignored. This issue now moves to the House, where it will be

interesting to see if Representatives are as poorly informed as Senators as

to what is actually going on.

 

Yes, the FDA is going into the drug development business. According to

Senate bill S.1082, the purpose of the Foundation is to advance the mission

of the Food and Drug Administration to modernize medical, veterinary, food,

food ingredient, and cosmetic product development, accelerate innovation,

and enhance product safety. It will do this by taking into consideration the

Critical Path reports and priorities published by the Food and Drug

Administration, identify unmet needs in the development, manufacture, and

evaluation of the safety and effectiveness, including postapproval, of

devices, including diagnostics, biologics, and drugs, and the safety of

food, food ingredients, and cosmetics.

 

The board of directors is composed of four primary members: the Commissioner

of the FDA, the Director of the National Institutes of Health, the Director

of the Centers for Disease Control and Prevention, the Director of the

Agency for Healthcare Research and Quality. These members will then select

the remaining board members to be composed of 4 representatives from Big

Pharma and Big Biotech, 3 representatives from academia (which is funded by

Big Pharma), 2 more from the FDA and NIH, 2 from consumers groups, and 1

from health care providers. This means that the FDA/Big Pharma/Big Biotech

voting block always has 13 votes -- to at the most 3. An executive director

of the Foundation will be appointed by the board and serve at the pleasure

of the board.

 

The bill says the Foundation will ensure that " action is taken as necessary

to enable the licensing of inventions developed by the Foundation or with

funds from the Foundation; and © executed licenses, memoranda of

understanding, material transfer agreements, contracts, and other such

instruments, promote, to the maximum extent practicable, the broadest

conversion to commercial and noncommercial applications of licensed and

patented inventions of the Foundation. "

 

Since the Foundation is responding to the needs of the Critical Path

Initiative, and that initiative is primarily about the development of new

drugs, it is clear that the Foundation will not only help with drug

development but it will have significant business relationships as a result.

Do not be confused by the Foundation's non-profit status, this is simply a

useful vehicle that SRI International has used to coordinate collaboration

while securing patents and licenses and then spinning off business ventures.

The FDA is trying to reduce its legal liability to the federal government by

setting up the Regan-Udall Foundation as a non-profit, in case the drugs it

helps design injure or kill people. Make no mistake about it, the FDA will

be fully in control of the Reagan-Udall Foundation for the FDA. Once this

becomes law, as anticipated by September 30, 2007, we will enter a new era

with the FDA as a quasi drug company.

 

 

A Safety Nightmare

It is indeed disturbing that SRI International is intimately involved with

the drug development process and has equally extensive connections with

Homeland Security and the Defense Department. It will be far easier to make

biological weapons that disrupt gene function than it will be to cure

anything, in terms of initial applications of Critical Path technology.

Indeed, this is an international problem and could cause an arms race of a

new sort, as the Reagan-Udall licensed technology moves out into the world

and not only creates a generic biotech drug industry but a generic biotech

military industry. It would be responsible for the Congress to actually

consider this problem before letting the Jeanie out of the bottle.

 

On the drug development side von Eschenbach plans to replace clinical trials

that show positive outcomes such as true improvement in the medical

condition or improved life expectancy with studies based on biomarkers or

surrogate endpoints. Biomarkers are like sign posts that point the way, but

do not guarantee that anything positive is actually happening. This concept

lowers the safety and effectiveness testing required to get an approval, a

key theme of the Critical Path Initiative.

 

This use of biomarkers, in and of itself, represents a drastic reduction in

safety for Americans. One example of this problem is the Avandia scandal,

wherein the drug was approved based on its ability to lower blood sugar (a

surrogate endpoint or biomarker). It turns out that the drug does so while

increasing the risk for heart failure, heart attack, and mortality. Over an

eight year period it was turned into a blockbuster drug with sales of 3.2

billion a year. During this time the FDA sat on the known risks and did

almost nothing to determine the aftermarket safety of the drug. The problem

was actually exposed by an independent researcher. Based on last year's drug

sales and the increased risk for heart attack, it is likely that 35,000

people needlessly died last year alone. How will independent researchers

expose problems in the future when all of the advance technology required to

evaluate the issue is part of an FDA-controlled monopoly?

 

Biotech drugs are inherently dangerous as they throw gene switches and

powerfully influence functions of the body. Our understanding of what we are

doing is in its infancy. This is like having the discovery of matches to

light fires and not having any firefighting equipment or technology. Take

the biotech company Amgen, with annual sales of 14.3 billion in 2006, and

nearly half that revenue coming from two biotech drugs, Epogen and Aranesp,

used in kidney disease. Aranesp is the blockbuster with 4.1 billion in sales

for 2006, and is also used to treat anemia during chemotherapy. Amgen stock

and sales are taking a beating as it is now coming to light that these drugs

pose a significant risk for increased death when used, and doctors keep

using them in an inappropriate way even though the FDA has warned them not

to.

 

The FDA is scrambling to contain the damage the drug is causing without

making Amgen look bad. Otherwise, the whole fast track approval of new

biotech drugs as envisioned by the Critical Path Initiative and Reagan-Udall

Foundation is in jeopardy. This is because these Amgen drugs were approved

by the FDA based on biomarkers, not based on improved patient outcomes. An

FDA Advisory panel was surprised to find how little testing Amgen did to

demonstrate these drugs are safe or actually improve the patient's health.

Amgen has a long history of involvement with the American Cancer Society and

its fundraising activities. Will an FDA chief that is beholden to the same

circle of friends and a true believer in what Amgen stands for actually be

able to objectively regulate the company and protect patients from danger?

Or will the profits of the drug company and image of the Critical Path

Initiative be more important?

 

 

The Loss of Patient Centered Care

There was a time when a patient walking into the doctor's office actually

had a meaningful conversation. The amount of time spent and the type of lab

work or diagnostics performed were not constrained by managed care. To the

best of the doctor's ability, the patient was given personalized care in the

best interest of the patient. Patient centered care has been replaced by

time constraints, minimized diagnostics, and maximized dispensing of

questionable drugs. All of these problems are about to get significantly

worse, as we enter the new era of von Eschenbach's concept of personalized

medicine, based on genomics and proteomics.

 

Initially, a flood of new biotech drugs will hit the market, resulting in

numerous Avandia and Vioxx-like scandals, which in some cases may take

several years to identify. Congress, with 20-20 hindsight, will hold

hearings that will result in legislation to improve safety. Von Eschenbach

will tell Congress that the fault is not the drugs. Rather, it is the

inability to personalize those drugs to specific patients that is the

problem. Von Eschenbach would love to say that today, but he knows he

doesn't have the technology ready to implement this plan as he will in five

years. Thus, he is willing to put the lives of hundreds of thousands of

innocent Americans in jeopardy by exposure to barely tested biotech drugs

and recklessly push forward with his Critical Path Initiative plan.

 

The Von Eschenbach solution will be to evaluate the blood of every patient

taking the drug with the FDA's sophisticated biomarker software. The FDA has

already developed the early stages of this software and will continue to

perfect its new system of medicine over the next decade. Making a long story

short, in order to receive medical care your blood will be evaluated by an

FDA-controlled super computer, your genes will be profiled, your genetic

weaknesses will be part of your medical record, and you will have an RFID

chip in your arm storing your complex biological medical records, tracking

your vital signs, and monitoring your whereabouts. If doctors think they

have it bad now just wait until they become slaves to the FDA computer's

directions and drug prescriptions -- which will no doubt be the latest and

most expensive biotech drug experiment.

 

 

Loss of Health Options

The FDA knows that most of its Critical Path technology is years from

practical application, thus it is confronted by the problem of maintaining

funding while not much is happening. One aspect of this technology is very

advanced toxicology tools, tools required for the development of new drugs.

In January of this year the FDA issued a press release saying they want to

use Critical Path science to develop tools to assist with their regular FDA

duties:

 

Scientific advances hold the potential to improve the tools FDA uses to

evaluate the safety and efficacy of human and veterinary products as well as

the safety and nutrition of food and food ingredients (e.g., new rapid tests

for biological and chemical contamination of animal-derived foods,

technologies for detecting and mitigating the microbial contamination of

food, analysis technologies for assessing the safety and nutritive value of

foods and food ingredients).

 

While any person is in favor of the FDA being able to better identify

contamination in food, such as infectious E.coli, assessing the safety of

food and food ingredients is an entirely different matter. Similar language

has been written into S.1082 in the section on the Reagan-Udall Foundation

for the FDA, meaning the FDA is seeking to have it written into law that it

can use Critical Path toxicology assessment to determine the safety of food

ingredients (i.e., dietary supplements). This becomes a vehicle for the FDA

to be able to remove any dietary supplement it desires from the market at

its whim.

 

The supplements most likely to be removed are those that compete with Big

Pharma and Big Biotech drugs, especially those drugs produced by the

Reagan-Udall Foundation itself. S.1082 already contains the troublesome

wording. The battle now moves to the House where it is vital to get an

amendment into this legislation that will protect dietary supplements

without interfering with the FDA's ability to identify true food

contamination problems. This amendment has been prepared by Jonathan Emord,

our nation's top health freedom attorney.

 

To keep up to date on this legislation and to help preserve your access to

dietary supplements, send an email your Senators and Representative by

clicking here.

 

A great deal will be happening in the next month or two on this legislation,

which will determine the future of health care safety and quality for many

years to come. Ideally, the Reagan-Udall Foundation for the FDA should be

removed from this legislation altogether until the technology is ready and

the safety can be assured. Realistically, both the Senate and House are

going to pass this legislation with the Reagan-Udall Foundation in the

bill -- unless massive public protest occurs.

 

Assuming that the Reagan-Udall Foundation does move forward, strong language

will need to be in this legislation to preserve health freedom and protect

consumers from having dietary supplements evaluated using drug-related risk

benefit analysis. In addition to the Emord amendment it will be essential to

protect ourselves from the FDA's internal conflicts of interest that pervade

the agency. As things are now the FDA is more concerned about looking good

and protecting its image than it is about drug safety or allowing unfettered

access to safe and effective forms of natural health options. Alternative

therapies and dietary supplements are the true competition to the FDA's Big

Pharma and Big Biotech medical model it is seeking to cram down the throats

of all Americans. Stay tuned -- more to come.

 

© 2007 Truth in Wellness, LLC - , reprinted with

permission.

 

 

About the author

Byron J. Richards, Founder/Director of Wellness Resources, is a

Board-Certified Clinical Nutritionist and nationally-renowned health expert,

radio personality, and educator. He is the author of Mastering Leptin, The

Leptin Diet, and Fight for Your Health: Exposing the FDA's Betrayal of

America.

 

Richards encourages individuals to take charge of their health, stand up for

their health rights, and not blindly succumb to propaganda from the

vested-interests who profit from keeping Americans sick. As founder of

Wellness Resources, Inc. of Minneapolis, MN, an independently-owned

fine-quality dietary supplement company since 1985, he has personally

developed 75 unique nutraceutical-grade nutritional formulas.

www.wellnessresources.com

 

FREE Subscription to Byron's Health Newsletter,